Signe T Andersen1, Daniel R Witte2,3, Henning Andersen4, Lasse Bjerg5,3,6, Niels Henrik Bruun5, Marit E Jørgensen6,7, Nanna B Finnerup4,8, Torsten Lauritzen5, Troels S Jensen4,8, Hatice Tankisi9, Morten Charles5. 1. Section for General Medical Practice, Department of Public Health, Aarhus University, Aarhus, Denmark sta@ph.au.dk. 2. Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark. 3. Danish Diabetes Academy, Odense, Denmark. 4. Department of Neurology, Aarhus University Hospital, Aarhus, Denmark. 5. Section for General Medical Practice, Department of Public Health, Aarhus University, Aarhus, Denmark. 6. Clinical Epidemiology, Steno Diabetes Center Copenhagen, Gentofte, Denmark. 7. National Institute of Public Health, University of Southern Denmark, Odense, Denmark. 8. Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 9. Department of Clinical Neurophysiology, Aarhus University, Aarhus, Denmark.
Abstract
OBJECTIVE: To study cardiometabolic risk-factor trajectories (in terms of levels and changes over time) preceding diabetic polyneuropathy (DPN) 13 years after a screen-detected diagnosis of type 2 diabetes. RESEARCH DESIGN AND METHODS: We clinically diagnosed DPN in a nested case-control study of 452 people in the Danish arm of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION). By linear regression models, we estimated preceding risk-factor trajectories during 13 years. Risk of DPN was estimated by multivariate logistic regression models of each individual's risk-factor trajectory intercept and slope adjusting for sex, age, diabetes duration, height, and trial randomization group. RESULTS: Higher baseline levels of HbA1c (odds ratio [OR] 1.76 [95% CI 1.37; 2.27] and OR 1.68 [95% CI 1.33; 2.12] per 1% and 10 mmol/mol, respectively) and steeper increases in HbA1c over time (OR 1.66 [95% CI 1.21; 2.28] and OR 1.59 [95% CI 1.19; 2.12] per 1% and 10 mmol/mol increase during 10 years, respectively) were associated with DPN. Higher baseline levels of weight, waist circumference, and BMI were associated with DPN (OR 1.20 [95% CI 1.10; 1.31] per 5 kg, OR 1.27 [95% CI 1.13; 1.43] per 5 cm, and OR 1.24 [95% CI 1.12; 1.38] per 2 kg/m2, respectively). CONCLUSIONS: Both higher levels and slopes of HbA1c trajectories were associated with DPN after 13 years. Our findings indicate that the rate of HbA1c increase affects the development of DPN over and above the effect of the HbA1c level. Furthermore, this study supports obesity as a risk factor for DPN.
OBJECTIVE: To study cardiometabolic risk-factor trajectories (in terms of levels and changes over time) preceding diabetic polyneuropathy (DPN) 13 years after a screen-detected diagnosis of type 2 diabetes. RESEARCH DESIGN AND METHODS: We clinically diagnosed DPN in a nested case-control study of 452 people in the Danish arm of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION). By linear regression models, we estimated preceding risk-factor trajectories during 13 years. Risk of DPN was estimated by multivariate logistic regression models of each individual's risk-factor trajectory intercept and slope adjusting for sex, age, diabetes duration, height, and trial randomization group. RESULTS: Higher baseline levels of HbA1c (odds ratio [OR] 1.76 [95% CI 1.37; 2.27] and OR 1.68 [95% CI 1.33; 2.12] per 1% and 10 mmol/mol, respectively) and steeper increases in HbA1c over time (OR 1.66 [95% CI 1.21; 2.28] and OR 1.59 [95% CI 1.19; 2.12] per 1% and 10 mmol/mol increase during 10 years, respectively) were associated with DPN. Higher baseline levels of weight, waist circumference, and BMI were associated with DPN (OR 1.20 [95% CI 1.10; 1.31] per 5 kg, OR 1.27 [95% CI 1.13; 1.43] per 5 cm, and OR 1.24 [95% CI 1.12; 1.38] per 2 kg/m2, respectively). CONCLUSIONS: Both higher levels and slopes of HbA1c trajectories were associated with DPN after 13 years. Our findings indicate that the rate of HbA1c increase affects the development of DPN over and above the effect of the HbA1c level. Furthermore, this study supports obesity as a risk factor for DPN.
Authors: Amy E Rumora; Kai Guo; Fadhl M Alakwaa; Signe T Andersen; Evan L Reynolds; Marit E Jørgensen; Daniel R Witte; Hatice Tankisi; Morten Charles; Masha G Savelieff; Brian C Callaghan; Troels S Jensen; Eva L Feldman Journal: Ann Clin Transl Neurol Date: 2021-05-06 Impact factor: 4.511
Authors: Haifa Maalmi; Kristiaan Wouters; Christian Herder; Nicolaas C Schaper; Hans H C M Savelberg; Jeroen H P M van der Velde; Jos P H Reulen; Werner Mess; Casper G Schalkwijk; Coen D A Stehouwer; Michael Roden; Dan Ziegler Journal: BMJ Open Diabetes Res Care Date: 2021-01